PMID- 11522518
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1878-5832 (Electronic)
IS  - 1359-6446 (Linking)
VI  - 6
IP  - 17
DP  - 2001 Sep 1
TI  - Delivery systems for DNA-binding drugs as gene expression modulators.
PG  - 893-904
AB  - Despite the large number of publications describing the synthesis and 
      physicocharacterization of the binding between drugs and DNA, relatively few 
      examine drug delivery systems (DDSs) for these molecules. The aim to find DDSs 
      for DNA-binding drugs (DBDs) was prompted mainly to reduce the toxicity and/or 
      enhance the tumor specificity of systemically administered drugs. With this in 
      mind, we have reviewed the biological effects of some DBDs that are currently 
      used as antitumor drugs and describe a brief selection of DDSs currently in 
      clinical trials or on the market.
FAU - Cortesi, R
AU  - Cortesi R
AD  - Dipartimento di Scienze Farmaceutiche, via Fossato di Mortara 19, 44100, Tel.: 
      +39 0532 291259; fax: +39 0532 291296, Ferrara, Italy
FAU - Nastruzzi, C
AU  - Nastruzzi C
LA  - eng
PT  - Journal Article
PL  - England
TA  - Drug Discov Today
JT  - Drug discovery today
JID - 9604391
EDAT- 2001/08/28 10:00
MHDA- 2001/08/28 10:01
CRDT- 2001/08/28 10:00
PHST- 2001/08/28 10:00 [pubmed]
PHST- 2001/08/28 10:01 [medline]
PHST- 2001/08/28 10:00 [entrez]
AID - S1359-6446(01)01893-1 [pii]
AID - 10.1016/s1359-6446(01)01893-1 [doi]
PST - ppublish
SO  - Drug Discov Today. 2001 Sep 1;6(17):893-904. doi: 10.1016/s1359-6446(01)01893-1.